Article Text

Download PDFPDF

Protocol
Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis
  1. Xiaofang Tang1,
  2. Qiancheng Hu2,
  3. Ye Chen2,
  4. Xin Wang2,
  5. Xiaofen Li2,
  6. Ke Cheng2,
  7. Dan Cao2
  1. 1 Department of Emergency; Disaster Medical Center, Sichuan University West China Hospital, Chengdu, Sichuan, China
  2. 2 Department of Abdominal Oncology, Cancer Center, Sichuan University West China Hospital, Chengdu, Sichuan, China
  1. Correspondence to Dr Dan Cao; caodan316{at}163.com

Abstract

Introduction The optimal dose-fractionation schedule of palliative radiotherapy has been debated in patients with bone metastases. Our objective is to comprehensively compare multiple fraction schedules with single fraction radiotherapy in terms of efficacy and toxicities by performing a systematic review and network meta-analysis.

Methods and analysis Electronic searches of titles/abstracts of palliative radiotherapy for bone metastases will be performed, using PubMed, Cochrane Library, Embase, clinical trials, American Society for Therapeutic Radiology and Oncology and European Society of Radiotherapy and Oncology. The primary outcome of interest is the incidence of skeletal-related event following palliative radiotherapy for bone metastases in prospective studies. The risk of bias and quality of evidence will be evaluated based on Cochrane Collaboration’s tool and Grades of Recommendation, Assessment, Development and Evaluation in the network meta-analysis. We will conduct subgroup analysis and sensitivity analysis regardless of heterogeneity estimates.

Ethics and dissemination This study will synthesise the evidence regarding dose-fractionation schedule of palliative radiotherapy in patients with bone metastases. We hope the findings from this study will help clinicians and patients select optimum palliative radiotherapy by identifying the optimal dose-fractionation schedule of palliative radiotherapy with the most value in terms of patient-important outcomes. The evidence obtained from network meta-analysis will help to guide head-to-head research in the future. The results will be disseminated through international conference reports and peer-reviewed manuscripts. Ethics review board is not required for this network meta-analysis.

PROSPERO registration number CRD42019135195.

  • bone metastases
  • palliative radiotherapy
  • network meta-analysis
  • protocol
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • XT and QH are joint first authors.

  • Contributors QH and DC conceptualised the network meta-analysis. QH and XW codeveloped the search strategy. Both XT and QH were major contributors in writing the manuscript. The protocol was revised by DC,YC, XL and KC. DC was serving as guarantor and corresponding author of this study. All authors approved the final manuscript and agreed to submit the protocol in the journal.

  • Funding The network meta-analysis was supported by the National Natural Science Foundation of China (grant no. 81773097).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.